Fractalkine-CX3CR1 Axis in Periodontal Therapy
Fractalkine and CX3CR1 Dynamics in Gingivitis and Periodontitis Before and After Therapy
2 other identifiers
interventional
90
1 country
1
Brief Summary
This study aimed to evaluate gingival crevicular fluid (GCF) levels of fractalkine/CX3CL1 and CX3CR1 in patients with gingivitis and periodontitis before and after non-surgical periodontal therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2023
CompletedFirst Submitted
Initial submission to the registry
December 13, 2025
CompletedFirst Posted
Study publicly available on registry
December 29, 2025
CompletedDecember 29, 2025
December 1, 2025
1.5 years
December 13, 2025
December 13, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in the levels of biochemical parameters
The levels of Fractalkine and CX3CR1 before and after periodontal treatment in gingivitis and periodontitis patients.
Baseline and 1 and 3 months after treatment
Study Arms (3)
stage 3 periodontitis
ACTIVE COMPARATORGCF samples were collected at baseline and at 1 and 3 months after treatment from periodontitis patients.
Gingivitis
ACTIVE COMPARATORGCF samples were collected at baseline and at 1 and 3 months after treatment from gingivitis patients.
Periodontally healthy controls
NO INTERVENTIONGCF samples were collected from periodontally healthy controls at baseline for once.
Interventions
Scaling and root planing, oral hygiene education and motivation.
Eligibility Criteria
You may qualify if:
- years of age
- having at least 20 natural teeth, excluding third molars
- having no systemic disease
- non-smokers
- criteria for healthy control group: BOP \< 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction
- criteria for stage 3 periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond.
You may not qualify if:
- having any systemic diseases,
- smoking
- current pregnancy or lactation
- a history of periodontal treatment in the past 6 months
- using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Giresun University
Giresun, Turkey, 28100, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assoc. Prof.
Study Record Dates
First Submitted
December 13, 2025
First Posted
December 29, 2025
Study Start
May 15, 2022
Primary Completion
November 15, 2023
Study Completion
December 10, 2023
Last Updated
December 29, 2025
Record last verified: 2025-12